The European Union's drugs regulator has recommended approval of Gilead Sciences' lenacapavir, a twice-yearly injection, for ...

Biopharmaceuticals stock Gilead Sciences ( GILD 3.08%) jumped 2.5% through 12:30 p.m. ET Friday after Needham & Co. upgraded ...

Similarly, Gilead has provided nearly $35.8 million in total philanthropic support for Black women-led and/or Black ...

An epidemic that's been sustained for 44 years might finally be quelled, with the milestone approval of the first HIV drug ...

Gilead upgraded to Buy by Needham as Yeztugo gains physician favor, with sales forecast to reach $6.4 billion by 2035, ...

Gilead Sciences (GILD) stock gains as Needham upgrades the company to Buy from Hold citing its new HIV prevention injectable, ...

Gilead (NASDAQ:GILD) announced Friday that an expert panel of the EU drug regulator, the European Medicines Agency (EMA) as ...

LONDON -- The European Medicines Agency has recommended authorizing a twice-yearly injectable drug aimed at preventing HIV, ...

The European Medicines Agency has recommended authorizing a twice-yearly injectable drug aimed at preventing HIV, which ...

Long-acting lenacapavir has been shown to be a promising option for HIV PrEP and is now recommended globally by WHO, with a ...

Gilead Sciences (NASDAQ:GILD) announced on Friday that the European Medicines Agency’s Committee for Medicinal Products for ...

The World Health Organization on Monday recommended Gilead's lenacapavir, a twice-yearly injection, as a tool to prevent HIV ...